Archives of Pharmacal Research

, Volume 35, Issue 2, pp 197–200

Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery

Report on Investigational Drugs


Multi-targeted hybrids combine two drugs in a single molecule to have greater medicinal effects than its individual components. Recently, a number of anti-cancer drug candidates such as CUDC-101 (Curis) have been designed based on linking properly two selected pharmacophores endowed with activity against different therapeutic targets.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Cai, X., Zhai, H.-X., Wang, J., Forrester, J., Qu, H., Yin, L., Lai, C.-J., Bao, R., and Qian, C., Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J. Med. Chem., 53, 2000–2009 (2010).PubMedCrossRefGoogle Scholar
  2. Dancey, J. E. and Chen, H. X., Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov., 5, 649–659 (2006).PubMedCrossRefGoogle Scholar
  3. Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., and Pavletich, N. P., Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 401, 188–193 (1999).PubMedCrossRefGoogle Scholar
  4. Frew, A. J., Johnstone, R. W., and Bolden, J. E., Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett., 280, 125–133 (2009).PubMedCrossRefGoogle Scholar
  5. Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., and Chen, Y. Z., Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov., 8, 111–128 (2009).PubMedCrossRefGoogle Scholar
  6. Lai, C. J., Bao, R., Tao, X., Wang, J., Atoyan, R., Qu, H., Wang, D. G., Yin, L., Samson, M., Forrester, J., Zifcak, B., Xu, G. X., DellaRocca, S., Zhai, H. X., Cai, X., Munger, W. E., Keegan, M., Pepicelli, C. V., and Qian, C., CUDC-101, a multitargeted Inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res., 70, 3647–3656 (2010).PubMedCrossRefGoogle Scholar
  7. Lehár, J., Krueger, A. S., Averyl, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., Lee, M. S., Zimmermann, G. R., and Borisy, A. A., Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol., 27, 659–666 (2009).PubMedCrossRefGoogle Scholar
  8. Korcsmáros, T., Szalay, M. S., Böde, C., Kovács, I. A., and Csermely, P., How to design multi-target drugs: target search options in cellular networks. Expert Opin. Drug Discov., 2, 1–10 (2007).CrossRefGoogle Scholar
  9. Mahboobi, S., Dove, S., Sellmer, A., Winkler, M., Eichhorn, E., Pongratz, M., Ciossek, T., Baer, T., Maier, T., and Beckers, T., Design of chimeric histone deacetylase and tyrosine kinase inhibitors: A series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-R?, and histone deacetylases. J. Med. Chem., 52, 2265–2279 (2009).PubMedCrossRefGoogle Scholar
  10. Mahboobi, S., Sellmer, A., Winkler, M., Eichhorn, E., Pongratz, H., Ciossek, T., Baer, T., Maier, T., and Beckers, T., Novel chimeric histone deacetylase inhibitors: A series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity. J. Med. Chem., 53, 8546–8555 (2010).PubMedCrossRefGoogle Scholar
  11. Meunier, B., Hybrid molecules with a dual mode of action: dream or reality? Acc. Chem. Res., 41, 69–77 (2008).PubMedCrossRefGoogle Scholar
  12. Morphy, R., Kay, C., and Rankovic, Z., From magic bullets to designed multiple ligands. Drug Discov. Today, 9, 641–651 (2004).PubMedCrossRefGoogle Scholar
  13. Morphy, R. and Rankovic, Z., Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem., 48, 6524–6543 (2005).CrossRefGoogle Scholar
  14. Sharma, S. V., Bell, D. W., Settleman, J., and Haber, D. A., Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer, 7, 169–181 (2007).PubMedCrossRefGoogle Scholar
  15. Stamos, J., Sliwkowski, M. X., and Eigenbro, C., Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem., 277, 46265–46272 (2002).PubMedCrossRefGoogle Scholar
  16. Tavera-Mendoza, L. E., Quach, T. D., Dabbas, B., Hudon, J., Liao, X., Palijan, A., Gleason, J. L., and White, J. H., Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist. Proc. Natl. Acad. Sci. U. S. A., 105, 8250–8255 (2008).PubMedCrossRefGoogle Scholar
  17. Vizirianakis, I. S., Chatzopoulou, M., Bonovolias, I. D., Nicolaou, I., Demopoulos, V. J., and Tsiftsoglou, A. S., Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives. J. Med. Chem., 53, 6779–6810 (2010).PubMedCrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea and Springer Netherlands 2012

Authors and Affiliations

  1. 1.College of PharmacyWoosuk UniversityWanjuKorea

Personalised recommendations